Welcome to the Virtual Tour for Referring Pulmonologist & HCPs

Breakthrough Technology for Severe Emphysema

Helping Patients Breathe Easier, Do More, and Enjoy Life

The Zephyr® Valve delivers durable clinical benefits — without surgery and its associated risks.1-5

Patients experience:1-5

  • Improved health status
  • Improved lung function
  • Increased exercise capacity
  • Reduced breathlessness or dyspnea
  • Reduced gas trapping
  • Improved quality of life
2020-GOLD-Evidence-A-Zephyr-Valve
20000-Patients-Treated-Globally-Zephyr

Pulmonologist Perspective: 
How Zephyr Valves Work

Physician-Testimonial-2

Zephyr Valve Patient Benefits

COPD-Emphysema-Disease-Progression
Staircase+Liberate-01
How-Zephyr-Valve-Works-COPD-Emphysema

How It Works

See how the Zephyr Valve treatment is performed as a minimally invasive lung volume reduction procedure to reduce hyperinflation and gas trapping in patients with severe emphysema. The Zephyr Valve is the first endobronchial valve to receive approval from the FDA for patients with either heterogenous or homogeneous emphysema.

Key-Patient-Selection

Key Patient Selection Criteria

  • Confirmed diagnosis of COPD
  • Non-smoking or willing to quit smoking
  • FEV1≤50% predicted
  • Breathless despite optimal medical management (mMRC≥2)
Education-Case-Support

Making a Referral:

Patients who might benefit from Zephyr Valve therapy include

  • Patients who are not responding to optimal medical management
  • Patients who prefer additional treatment options
Patient-Confirmation

Once Referred an Interventional Pulmonologist Will Confirm

  • Diagnosis of severe emphysema
  • Presence of hyperinflation (RV≥175% predicted)
  • Confirmation the target lobe has little to no collateral ventilation

Clinical Evidence

  • 4 RCTs published using Zephyr Valve and Chartis® to preselect patients1-5
  • Published in the New England Journal of Medicine, The Lancet, and The American Journal of Respiratory and Critical Care Medicine1-5,16
  • Statistically significant and clinically meaningful improvements compared to standard of care in multiple trials1-4
  • Treatment success seen in a broad range of primary and secondary endpoints1-5

Consistent Clinical Findings Across Four Randomized Controlled Trials

RCTDesignSample size & follow-up periodProcedural Success (TLVR%)Difference Zephyr Valve vs. Control Groups (ITT)
Lung
function
(fev1%)
MCID = 10%-15%
Excercise capacity
(6mwd)
MCID = 26 m
quality
of life
(sgrq)
MCID = -4 pts
LIBERATE12:1 Randomization
Heterogeneous only
Multicenter
n=190
12 months
84%18.0%
p<0.001
39 m
p=0.002
-7.1 pts
p=0.004
TRANSFORM22:1 Randomization
Heterogeneous only
Multicenter
n=97
6 months
90%29.3%
p<0.001
79 m
p<0.001
-6.5 pts
p=0.031
IMPACT31:1 Randomization
Homogeneous only
Multicenter
n=93
6 months*
89%16.3%
p<0.001
28 m
p=0.016
-7.5 pts
p<0.001
STELVIO4,51:1 Randomization
Heterogeneous & Homogeneous
Single Center
n=68
6 months
88%17.8%
p=0.001
74 m
p<0.001
-14.7 pts**
p<0.001
*Data on file at PMX (not in publication)
**Completed cases, all other values listed are ITT population
T Difference between valve and control groups
Pulmonx-Zephyr-Clinical-Study-Summary-Table
*Completed cases, all other values listed are ITT population

Featured Patient Stories

LIBERATE1 Primary & Secondary Endpoints

Primary Endpoint Responder Analysis

Percent of Subjects with FEV1 Change of ≥15%
LIBERATE - Percent of Subjects with FEV1 Change of ≥15% at 12 Months | amCharts

Secondary Endpoints

Change in St. George’s Resp Questionnaire
LIBERATE - SGRQ - Line | amCharts
Change in FEV1
LIBERATE - FEV1 - Line | amCharts
Change in 6MWD
LIBERATE - 6MWD - Line | amCharts

Zephyr Valve Procedure

Complications of the Zephyr Endobronchial Valve Treatment include but are not limited to pneumothorax, worsening of COPD symptoms, hemoptysis, pneumonia, dyspnea and, in rare cases, death.

Chat with Us

  • This field is for validation purposes and should be left unchanged.

ATS-2020
GLO-EN-607-v2

Privacy Preference Center